WO2012136813A2 - Agents for medical radar diagnosis - Google Patents

Agents for medical radar diagnosis Download PDF

Info

Publication number
WO2012136813A2
WO2012136813A2 PCT/EP2012/056363 EP2012056363W WO2012136813A2 WO 2012136813 A2 WO2012136813 A2 WO 2012136813A2 EP 2012056363 W EP2012056363 W EP 2012056363W WO 2012136813 A2 WO2012136813 A2 WO 2012136813A2
Authority
WO
WIPO (PCT)
Prior art keywords
radar
contrast agent
sample
marker
human
Prior art date
Application number
PCT/EP2012/056363
Other languages
French (fr)
Other versions
WO2012136813A9 (en
WO2012136813A3 (en
Inventor
Jo Klaveness
Original Assignee
Universitetet I Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet I Oslo filed Critical Universitetet I Oslo
Publication of WO2012136813A2 publication Critical patent/WO2012136813A2/en
Publication of WO2012136813A3 publication Critical patent/WO2012136813A3/en
Publication of WO2012136813A9 publication Critical patent/WO2012136813A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  using microwaves or terahertz waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Definitions

  • This invention relates to in vivo the use of agents or markers for medical diagnosis based on radar technology.
  • One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
  • Radar Radio detection and ranging
  • Radar systems are able to detect size, form, altitude, direction and speed of both fixed objects and moving objects.
  • Typical moving objects can be cars and other vehicles, aircrafts and space shuttles.
  • Use of radars today include both military use like air-defence systems and civil use like for example air traffic control , weather prognosis, geological radar mapping and various systems traffic monitoring systems.
  • Most radar systems monitor objects in a far distance from the radar electromagnetic source and radar monitoring system.
  • radar-based anti-collision systems for cars are able to monitor objects close to the cars.
  • US5,030,956 (Murphy) describes a radar tomography method and apparatus that generates a plurality of radar pulses in a transmitter and project them with an antenna toward a patient. Radar pulses reflected from the patient are picked up by the antenna and conducted to the receiver.
  • the described system in US5,030,956 is also able to produce three-dimensional information.
  • US2004/0249257 discloses an ultra-wide band radar known as micropower impulse radar that is combined with advanced signal processing techniques to provide a new type of medical imaging technology including frequency spectrum analysis and modern statistical filtering techniques to search for, acquire, track, and interrogate physiological data.
  • US2004/0019282 describes hybrid lidar- radar system for medical diagnostics. The radar system can be used for detecting tumors within tisues by detecting reflected signals from tissue and discriminating the information related to the tumor from the undesirable backscattering of light created by the tissue itself.
  • US2010/0234720 (Tupin) describes a system and method for extracting physiological data using ultra-wideband radar and improved signal processing techniques.
  • US2010/0292559 (Hannemann) describes a radar- equiped patient bed for a medical imaging apparatus and operating methods thereof.
  • US2009/0192384 (Fontius) describes a medical unit which comprises a three dimensional radar array for detection of positional or movement data of objects in an examination space and a processing unit for the evaluation of the detected data, with the processing unit being connected to the medical unit and the three dimensional radar array, and with the evaluated data being used to control the medical unit or for post-processing data acquired by the medical diagnostic or therapeutic unit.
  • WO2010/1241 17 (Lifewave) describes fetal and/or maternal monitoring devices, systems and methods using UWB medical radar.
  • These devices and systems may include a UWB sensor providing high-resolution and reliable simultaneous monitoring of multiple indicators of fetal and/or maternal health, such as fetal heart rate, fetal heart rate variability, fetal respiration, fetal gross body movement and other parameters during pregnancy.
  • fetal heart rate fetal heart rate variability
  • fetal respiration fetal gross body movement and other parameters during pregnancy.
  • Future use of radar medical imaging is also described by Yngve Vogt: Non-dangerous radar might replace X-ray in Appolon (University of Oslo), 2/2011 pages 36-37.
  • radar technology might be used for diagnosis of disease based on mapping of diseases tissue and by monitoring the signal reflected from the human body.
  • This signal has tended to be used in medical imaging to study natural events in which organ impedance changes occur (e.g. breathing, eating, blood flow, heart beating etc) with imaging optionally being assisted by artificially increasing the volume or fluid content of the organ under study, e.g. by administration of a meal, by increasing total blood volume, etc.
  • diagnostic imaging modalities such as X-ray, MRI, ultrasound and scintigraphy however, there has as yet been no suggestion that Ell might benefit from the use of contrast media, and in particular the use of parenterally administered contrast media, to improve organ or tissue contrast.
  • One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
  • agents materials which on administration will serve to enhance the diagnostic information typically by enhancing the contrast in the resulting images by modifying the reflection of the electromagnetic radiation from the tissue in those tissues, organs or ducts into which they distribute. Where such markers and contrast agents serve to modify the local reflection of tissue they will function as modifiers of the radiation reflection as a function of the concentration of markers or negative contrast agents in the tissue, organs or ducts where they are present.
  • agent, marker and contrast agent as used herein are synonymous and may be used interchangeably.
  • Such markers and contrast media may be administered enterally or, particularly preferably, parenterally.
  • Preferred parenteral administration route is intravascular administration, more preferably intravenous administration.
  • the invention relates to the use of agents or markers for medical diagnosis based on radar technology.
  • agents or markers for medical diagnosis based on radar technology One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
  • the present invention also relates to a method of diagnosis of (or imaging) a sample (e.g. a human or non-human animal subject) comprising a radar marker or radar contrast agent, said method comprising:
  • the marker or contrast agent interacts with radar radiation to a different extent than the medium of the sample in which it is located, such that the marker or contrast agent is detectable within the sample and capable of being rendered into an image showing its location within the sample.
  • One method of measuring the impact that a marker or contrast agent has on the radar radiation signal is by determining the Fresnel reflection coefficient of the marker or agent in a particular medium.
  • a high Fresnel reflection coefficient is indicative of having high contrast in that medium.
  • the imaging method preferably comprises the step of administering the radar marker or radar contrast agent to said sample (or subject). ln the imaging method, the radar marker or radar contrast agent is optionally dissolved or dispersed in a physiologically tolerable liquid carrier medium.
  • the present invention therefore relates to a method of diagnosis of (or imaging) a human or animal subject which method comprises:
  • a radar marker or a radar contrast agent optionally dissolved or dispersed in a physiologically tolerable liquid carrier medium, and
  • said marker or contrast agent being capable on dissolution or dispersion in water of yielding a fluid having an impact on the radar radiation signal in the subject.
  • the step of generating a radar based signal or image of at least part of said sample (or subject) preferably comprises
  • the invention relates to a method of producing an image of a sample containing a radar marker or radar contrast agent, said method comprising
  • the radar radiation is preferably emitted from a first antenna (e.g. in step a.), and detected at a second antenna (e.g. in step b.).
  • an array of antennas is used, such that the signal emitted from each antenna is detected by the remaining antennas in the array.
  • the step of generating a radar based signal or image of at least part of said sample (or subject) preferably comprises: i. subjecting the sample (or subject) to radar radiation emitted from one or transmitters;
  • processing the detected radar radiation by aligning the signals to generate two or more aligned signals which are synthetically focused on a desired volume of the sample (or subject), and processing the aligned signals to generate part of the image of the sample (or subject).
  • steps i., ii. and iii. are repeated until an image of the sample (or subject) has been generated.
  • Medical imaging using radar is known in the art and would be familiar to the skilled person.
  • This type of imaging is sometimes referred to as microwave imaging, or ultrawideband (UWB) microwave imaging.
  • the range of frequencies used in radar imaging typically varies from 0.1-40 GHz, preferably 0.5-20 GHz.
  • Step c. is typically done using a computer processor which generates an image of the sample (or subject) on a display device such as a computer screen. Algorithms to process signals detected from the one or more detecting antenna(s) are known in the art and would be familiar to the skilled person.
  • Step c. preferably comprises generating an image of the sample (or subject) showing the distribution of the contrast agent in the sample (or subject).
  • the method preferably further comprises the step of administering the contrast agent to the sample (or subject).
  • the method preferably further comprises the step of using the image of the subject to diagnose a disease in the subject, preferably a human or non-human animal subject.
  • the sample used in the method can be part of a human or non-human animal body, or alternatively a inanimate tissue sample which has been taken from a human or non-human animal body.
  • the method may be carried out on a synthetic mimic of human or non-human animal tissue. Such synthetic analogues are typically called "phantoms" in the art.
  • sample and “subject” as used herein are generally interchangeable.
  • subject is however generally used when referring to animate or live samples, such as human or non-human animals which are being imaged.
  • the present invention also relates to an imaging apparatus comprising
  • one or more antennas capable of emitting radar radiation to a defined volume and receiving radar radiation that has passed through that volume; and a computer processor for processing the signals received by the one or more antennas to form an image of the defined volume.
  • the defined volume is sized to accommodate a human body.
  • the apparatus of the invention preferably also comprises a sample which contains the radar contrast agent, wherein at least part of the sample is located in the defined volume.
  • the sample is inanimate (i.e. does not form part of a living organism).
  • the apparatus of the invention preferably also comprises a means for administering the radar contrast agent to a human or non-human animal, such as a syringe, a catheter or an enema kit.
  • the invention provides the use of a physiologically tolerable agents, markers and contrast agents which are capable of changing the reflection properties of radar radiation in the human body after administration of the agent, preferably in diagnosis of a disease in a human or non-human animal.
  • diagnosis is preferably by mapping of disease tissue by radar and by monitoring the signal reflected from the human or non-human animal.
  • the present invention also relates to contrast agents for use in diagnosis of a human or nonhuman animal by radar imaging.
  • the sample is preferably not located in an external (or applied) magnetic field.
  • contrast agent organic iodinated agents
  • metal chelates metal chelates
  • gas gas
  • magnetic iron oxide particles inorganic salts
  • organic iodinated agents are concerned, particular mention should be made of those agents already proposed in the literature for use as X-ray contrast agents.
  • examples of such materials include many compounds with low toxicity and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
  • X-ray contrast agents suited for use according to the present invention include in particular the iodinated contrast agents, especially those containing one or more, generally one or two, triiodophenyl groups in their structure.
  • the most preferred organic iodinated compounds to be used as markers and contrast agents for radar-based medical diagnosis are water-soluble agents comprising one or two benzene rings each substituteted with 3 iodine atoms.
  • the even more preferred agents are such agents without any charge in vivo; so- called non-ionic agents. These compounds have several alcohol groups to secure that the substances have high water-solubility without being a salt.
  • Preferred gents are the following compounds: diatrizoic acid, ioxaglinic acid, iomeprol, iobitriol, iohexol, iopamidol, iopentol, iodixanol, ioforminol, ioxaglate, ioxilan, iopromide, iotrolan, ioversol and iothalamate.
  • the even most preferred agents are the following compounds: iohexol, iopamidol, iopentol, iodixanol, ioforminol, ioxaglate, ioxilan, iopromide, iotrolan, ioversol and iothalamate.
  • Iohexol is the most preferred organic iodinated agent.
  • Particular organic iodinated compounds useful according to the invention thus, for example, include compounds described in US5,993,780 (Nycomed), US5,958,376 (Nycomed), US5,958,375 (Nycomed), US5,882,628 (Nycomed), US7,754,920 (GE Healthcare), UD7,662,859 (GE Healthcare), US7,592,482 (Bracco), US7,485,753 (GE Healthcare), US4,032,567 (Schering), US4,239,747 (Schering), US4,264,572 (Schering), US4,269,819 (Schering), US4,269,819 (Schering), US4,364,921 (Schering), US4,395,391 (Schering), US4,426,371 (Schering), US4,547,357 (Schering), US5,004,835 (Schering), US5,073,362 (Schering)US5, 183,654
  • the organic iodinated agents used in the present invention are preferably iodobenzene compounds (i.e. having iodine as a ring substituent on an aromatic C 6 ring), especially diiodo or more preferably triiodo benzene compounds, in particular diiodo and triiodo benzene compounds having the iodines at non- adjacent ring positions.
  • the iodobenzene ring is preferably also substituted by hydrophilic groups comprising one, two or three hydroxyl groups. Preferred hydrophilic groups include
  • X is a Ci-6 alkylene group, especially an ethylene and more especially propylene group
  • R 1 is hydrogen or a methyl group
  • n 1 , 2, or 3, preferably 2 or 3.
  • the most preferred iodinated agents are;
  • Metal Chelates Insofar as metal chelates are concerned, particular mention should be made of theoe agents already proposed in the literature for use as MRI contrast agents. Examples of such materials include many compounds with low toxicity and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
  • metal chelates suited for use according to the present invention include in particular paramagnetic chelates especially gadolinium chelates, dysprosium chelates, iron chelates and manganese chelates, especially those containing a chelating agent being an amino acid derivative like for example derivatives of EDTA, DTPA, DPDP, DOTA and D03A.
  • the most preferred metal chelates to be used as markers and contrast agents for radar-based medical diagnosis are water-soluble agents comprising gadolinium (3+) or manganese (2+). Both non-ionic chelates and ionic chelates are among the most preferred chelates for use as markers and contrast agents for radar-based medical diagnosis.
  • the even most preferred chelates are the following compounds: GdDTPA
  • Gdopentetate dimeglumine dimeglumine
  • GdDOTA glycoteric acid meglumine
  • GdDTPA-BMA gadodiamide
  • Gd2HP-D03A gadoteridol
  • MnDPDP mangafodipir
  • Non-ionic chelates are used as pharmaceutically acceptable salts like sodium salt, potassium salt or meglumine salt.
  • the most preferred chelates are:
  • Particular metal chelates useful according to the invention thus, for example, include compounds described in US7.767.196 (University of Hong Kong), US7,745,590 (University of Utah), US7,368,099 (Kyushu University), US4,647,447 (Schering), US4,957,939 (Schering), US4,963,344 (Schering), US 5,021 ,236 (Schering), US5,098,692 (Schering), US5, 277,895 (Schering), US5,316,756 (Schering), US5,334,371 (Schering), US5,362,475 (Schering), US5,403,572 (Schering), US5.419,894 (Schering), US5,560,903 (Schering), US5,595,725 (Schering), US4.916,246 (Bracco), US4,980,502 (Bracco), US5, 132,409 (Bracco), US5, 182,370 (Bracco), US
  • gases are concerned, particular mention should be made of those agents already proposed in the literature for use as ultrasound contrast agents and to some extent for use as gastrointestinal X-ray contrast agents.
  • examples of such materials include many compounds with low toxicity, low solubility in blood and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
  • gases suited for use according to the present invention include in air, sulfurhexafluoride and perfluorocarbons; for use within the vascular system gases with low solubility in blood are the most preferred gases.
  • Perfluorocarbons such as perfluoropropane and perfluorobutane are particularly preferred. The even most preferred gases for intravascular administration are
  • Perfluoropropane is the most preferred gas.
  • the most preferred agents gases for intravascular administration are preferably encapsulated into surfactants, phospholipids, carbohydrates, albumin or synthetic or semisynthetic polymer materials.
  • the even most preferred gas-based products according to the present invention are products like SonoVue, Sonazoid, Optison and Levovist.
  • Encapsulated gas-based compositions useful according to the invention thus, for example, include compounds described in US 6,221 ,337 (Nycomed), US6,274,120 (Nycomed), US5,674,468 (Nycomed), US5,670, 135 (Nycomed), US5,648,062 (Nycomed), US5,637,289 (Nycomed), US5,618,514 (Nycomed), US5,614, 169 (Nycomed), US5,569,449 (Nycomed), US5,567,412 (Nycomed), US5,558,856 (Nycomed), US5,558,857 (Nycomed), US5,536,490 (Nycomed), US5,529,766 (Nycomed), US6.217,850 (Nycomed), US6, 177,061 (Nycomed), US6,165,442 (Nycomed), US6, 110,44
  • Magnetic Iron Oxide Insofar as magnetic iron oxides are concerned, particular mention should be made of those agents already proposed in the literature for use as MRI contrast agents. Examples of such materials include any particulate ferromagnetic or
  • superparamagnetic material which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
  • magnétique iron oxides suited for use according to the present invention include any particulate iron oxide like magnetite (Fe304) or gamma-iron(lll)oxide. Both the particle size and the size of the iron oxide crystals might vary over a large range from a few nanometers to micrometers.
  • the iron oxide material might be encapsulated or coated with various organic materials like for example natural polymers, synthetic polymers, proteins, carbohydrates, polyethyleneglycols and other materials.
  • the even most preferred magnetic iron oxide-based products according to the present invention are products like Endorem (Feridex), Resovist, Sinerem, Combidex and Cliavist.
  • Iron oxide based compositions useful according to the invention thus, for example, include compounds described in US6, 123,920 (Nycomed), US5,545,395 (Bracco), US7,807,137 (University of Puerto Rico), US4,452,773 (Advanced Magnetics), US4,770,183 (Advanced Magnetics), US4,827,945 (Advanced Magnetics), US5, 102,652 (Advanced Magnetics), US5, 160,726 (Advanced Magnetics),
  • inorganic salts are concerned, particular mention should be made of those agents already proposed in the literature for use as X-ray contrast agents. Examples of such materials include any particulate insoluble material like for example barium sulphate. Inorganic salts are preferably administered directly into the gastrointestinal system by oral administration or by use of an enema
  • Barium salts are particularly preferred inorganic salts, with barium sulphate being the most preferred.
  • One further aspect of the present invention relates to use of liposome markers or as contrast agent in radar-based medical imaging. Liposomes are for example described in US6.217,849 (Bracco), US5,980,937 (Bracco), US5,702,722 (Bracco), US5,676,928 (Nycomed), US7,588,751 (Konica Minolta) and US7,785,568 (Marval Biosciences).
  • One further aspect of the present invention relates to use of targeted markers or as contrast agent in radar-based medical imaging.
  • Targeted markers and contrast agents are for example described in US6,051 ,207 (Nycomed), US6,264,917 (Nycomed), US5,414, 114 (Bracco), US6, 139,819 (lmaRx),US6,261 ,537
  • contrast agents have a Fresnel reflection coefficient of at least 0.15, more preferably at least 0.20, at frequencies of between 0.5 and 20 GHz (e.g. 5 GHz) with reference to healthy human blood as measured using a Agilent Network Analyzer N5245A at concentrations of 300 mg/ml.
  • healthy human blood blood that has recently been taken from a healthy human adult in which all blood markers such as platelet count, ion levels etc are within what would generally be deemed to be normal levels by a physician.
  • Particulate contrast agents for parenteral administration should preferably have particle sizes of no more than 1.5 micrometer, especially 1.0 micrometer or less.
  • Enteral administration of markers and contrast agents for radar based medical diagnosis including radar based medical imaging will preferably be by oral administration of the marker or contrast agent or by administration of the marker or contrast agent using an enema.
  • contrast agents according to the invention will generally be by injection or infusion, especially into the cardiovascular system.
  • markers or contrast media may also be administered into body cavities having external voidance ducts, e.g. by catheter into the bladder, uterus etc.
  • the dosages of markers and contrast agents for radar-based medical diagnosis used according to the invention will vary over a broad range depending on a variety of factors such as administration route, the pharmacodynamic properties of the contrast agent (the more widely distributing the agent is the larger the dose may be), the chemical and physical nature of the contrast agent, and the frequency of the electrical current applied in the impedance measurement.
  • agents will be administered in concentrations of 1 micromol/l to 1 mol/l, preferably 0.01 to 0.8 mmol/l and dosages will lie in the range 0.002 to 20 mmol/kg bodyweight, generally 0.005 to 10 mmol/kg.
  • the overall dosage will generally be 1 to 200 ml when administered into the cardiovascular system or 5 ml to 1.5 litres of marker or contrast agent when administered into a body cavity having an external voidance duct, e.g. by oral or rectal administration.
  • the markers and contrast agents according to the present invention may be used for a wide range of clinical indications with appropriate selection of the contrast agent (for its pharmacodynamic properties) and of the administration route.
  • non-absorbable markers and contrast agents for radar-based medical diagnosis are particularly useful in the gastrointestinal tract, for diagnosis of abnormalities therein or as markers of the gastrointestinal system.
  • Such agents may also be used for dynamic studies, for example of gastric emptying.
  • a pH control agent such as cimetidine to suppress naturally occuring pH variations which might otherwise reduce imaging accuracy.
  • Some of the marker and contrast agents are absorbable from the gastrointestinal trace and may be taken up by the liver and excreted into the bile. Such agents can thus be used for imaging the hepatobiliary system and for liver function studies even following oral rather than parenteral administration.
  • contrast may be enhanced by administration of a
  • physiologically active agent which serves to modify body fluid distribution, e.g. a diuretic, thereby causing image modification in body areas where body fluid is increased or decreased.
  • a physiologically active agent which serves to modify body fluid distribution, e.g. a diuretic, thereby causing image modification in body areas where body fluid is increased or decreased.
  • Preferred methods and uses described above utilise the preferred contrast agents mentioned herein.
  • preferred diseases are those diseases mentioned herein, such as diseases selected from abnormalities in the gastrointestinal tract, cancer and tumours such as for example breast cancer, lung cancer, liver cancer, metastisis, brain cancer and colorectal cancer; and infarcts or other cardiovascular diseases or cardiovascular events such as in the heart infarcts.
  • Example 1 lodinated marker and contrast agent for radar-based diagnosis including imaging
  • a solution of iohexol (Omnipaque) (300 mg /ml, 50 ml) is administered
  • the patient undergoes a radar-based diagnosis of the heart and the kidneys.
  • Gas-based marker and contrast agent for radar-based diagnosis including imaging
  • a suspension of encapsulated perfluoropropane (Optison) (0.19 mg/ml, 3 ml) is administered intravenously to a patient.
  • the patient undergoes a radar-based diagnosis of the cardiovascular system.
  • Optison encapsulated perfluoropropane
  • Metal chelate marker and contrast agent for radar-based diagnosis including imaging
  • GdDTPA bis-meglumine salt (Magnevist) (0.5 mmol/ml), 16 ml) is administered intravenouly to a patient.
  • the patient undergoes a radar-based diagnosis of the heart, brain and the renal system.
  • Magnetic iron oxide-based marker and contrast agent for radar-based diagnosis including imaging Magnetic iron oxide particles (Resovist) (0.25 mmol/ml, 10 ml) is administered intravenously to a patient. The patient undergoes a radar-based diagnosis of the cardiovascular system.
  • Imaging Magnetic iron oxide particles Repsovist
  • Inorganic salt marker and contrast agent for radar-based diagnosis including imaging
  • Barium sulphate (1 gram/ml, 400 ml) is administered as an enema to a patient. The patient undergoes a radar-based diagnosis of abdomen.
  • the permittivity is a measure of how the electrical field is affected by or affects the medium.
  • the permittivity in various contrast agents was determined using Agilent Network Analyzer N5245A with Agilent 5070E dielectric probe kit. (Agilent Technologies, USA).
  • the contrast agents were the following:
  • Particulate x-ray contrast agent Barium sulfate suspension: 40% w/v (30% v/v) (Tagitol-V (E-Z-EM, Canada)).
  • Ionic iodinated X-ray contrast agent 270 mg l/ml (diatrizoate sodium 100 mg/ml and diatrizoate meglumine 600 mg/ml, Gastrografin (Bayer Schering Pharma, Germany))
  • Non-ionic iodinated X-ray contrast agent 350 mgl/ml (iohexol.( Omnipaque. GE Healthcare, USA))
  • the conductivity in various contrast agents was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
  • the permittivity in dilued Multihance was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
  • the permittivity in dilued Gastrografin was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
  • the conductivity of diluted Gastrografin was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA). The conductivity data on diluted Gastrografin are shown in Figure 1 1 and Figure 12.
  • the permittivity in dilued Omnipaque was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
  • the conductivity of diluted Omnipaque was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
  • Omnipaque (iohexol) shows a surprisingly high Fresnel reflection coefficient.

Abstract

The present invention relates to the use of contrast agents in radar based imaging, particularly in medical imaging. The invention also relates to the use of contrast agents in diagnosis of various diseases using radar-based technology. An apparatus for radar-based imaging comprising a contrast agent is also disclosed.

Description

Agents for Medical Radar Imaging
This invention relates to in vivo the use of agents or markers for medical diagnosis based on radar technology. One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
Radar (Radio detection and ranging) is a system for detection of objects using specific electromagnetic waves. Radar systems are able to detect size, form, altitude, direction and speed of both fixed objects and moving objects. Typical moving objects can be cars and other vehicles, aircrafts and space shuttles. Use of radars today include both military use like air-defence systems and civil use like for example air traffic control , weather prognosis, geological radar mapping and various systems traffic monitoring systems. Most radar systems monitor objects in a far distance from the radar electromagnetic source and radar monitoring system. However, during the last years radar-based anti-collision systems for cars are able to monitor objects close to the cars.
Radar can also be used for medical diagnosis and radar-based medical imaging systems are in development. These systems might have a resolution of less than 1 cm maybe around 1 mm. US5,030,956 (Murphy) describes a radar tomography method and apparatus that generates a plurality of radar pulses in a transmitter and project them with an antenna toward a patient. Radar pulses reflected from the patient are picked up by the antenna and conducted to the receiver. The described system in US5,030,956 is also able to produce three-dimensional information. US2004/0249257 (Tupin) discloses an ultra-wide band radar known as micropower impulse radar that is combined with advanced signal processing techniques to provide a new type of medical imaging technology including frequency spectrum analysis and modern statistical filtering techniques to search for, acquire, track, and interrogate physiological data. US2004/0019282 (Mullen) describes hybrid lidar- radar system for medical diagnostics. The radar system can be used for detecting tumors within tisues by detecting reflected signals from tissue and discriminating the information related to the tumor from the undesirable backscattering of light created by the tissue itself. US2010/0234720 (Tupin) describes a system and method for extracting physiological data using ultra-wideband radar and improved signal processing techniques. US2010/0292559 (Hannemann) describes a radar- equiped patient bed for a medical imaging apparatus and operating methods thereof. US2009/0192384 (Fontius) describes a medical unit which comprises a three dimensional radar array for detection of positional or movement data of objects in an examination space and a processing unit for the evaluation of the detected data, with the processing unit being connected to the medical unit and the three dimensional radar array, and with the evaluated data being used to control the medical unit or for post-processing data acquired by the medical diagnostic or therapeutic unit. WO2010/1241 17 (Lifewave) describes fetal and/or maternal monitoring devices, systems and methods using UWB medical radar. These devices and systems may include a UWB sensor providing high-resolution and reliable simultaneous monitoring of multiple indicators of fetal and/or maternal health, such as fetal heart rate, fetal heart rate variability, fetal respiration, fetal gross body movement and other parameters during pregnancy. Future use of radar medical imaging is also described by Yngve Vogt: Non-dangerous radar might replace X-ray in Appolon (University of Oslo), 2/2011 pages 36-37.
Thus, on the whole, radar technology might be used for diagnosis of disease based on mapping of diseases tissue and by monitoring the signal reflected from the human body. This signal has tended to be used in medical imaging to study natural events in which organ impedance changes occur (e.g. breathing, eating, blood flow, heart beating etc) with imaging optionally being assisted by artificially increasing the volume or fluid content of the organ under study, e.g. by administration of a meal, by increasing total blood volume, etc. Unlike diagnostic imaging modalities such as X-ray, MRI, ultrasound and scintigraphy however, there has as yet been no suggestion that Ell might benefit from the use of contrast media, and in particular the use of parenterally administered contrast media, to improve organ or tissue contrast.
We now therefore propose the use of agents or markers for medical diagnosis based on radar technology. One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
By "agents", "markers" and "contrast agents" is meant materials which on administration will serve to enhance the diagnostic information typically by enhancing the contrast in the resulting images by modifying the reflection of the electromagnetic radiation from the tissue in those tissues, organs or ducts into which they distribute. Where such markers and contrast agents serve to modify the local reflection of tissue they will function as modifiers of the radiation reflection as a function of the concentration of markers or negative contrast agents in the tissue, organs or ducts where they are present. The terms agent, marker and contrast agent as used herein are synonymous and may be used interchangeably.
Such markers and contrast media may be administered enterally or, particularly preferably, parenterally. Preferred parenteral administration route is intravascular administration, more preferably intravenous administration.
Thus in one aspect the invention relates to the use of agents or markers for medical diagnosis based on radar technology. One preferred aspect of the present invention relates to agents as contrast agents in medical imaging based on radar radiation.
The present invention also relates to a method of diagnosis of (or imaging) a sample (e.g. a human or non-human animal subject) comprising a radar marker or radar contrast agent, said method comprising:
generating a radar-based signal or image of at least part of said sample (or subject), said marker or contrast agent being capable on dissolution or dispersion in water of yielding a fluid having an impact on the radar radiation signal in the sample (or subject).
By "having an impact" is meant that the marker or contrast agent interacts with radar radiation to a different extent than the medium of the sample in which it is located, such that the marker or contrast agent is detectable within the sample and capable of being rendered into an image showing its location within the sample.
One method of measuring the impact that a marker or contrast agent has on the radar radiation signal is by determining the Fresnel reflection coefficient of the marker or agent in a particular medium. A high Fresnel reflection coefficient is indicative of having high contrast in that medium.
The imaging method preferably comprises the step of administering the radar marker or radar contrast agent to said sample (or subject). ln the imaging method, the radar marker or radar contrast agent is optionally dissolved or dispersed in a physiologically tolerable liquid carrier medium. The present invention therefore relates to a method of diagnosis of (or imaging) a human or animal subject which method comprises:
administering to said subject a radar marker or a radar contrast agent, optionally dissolved or dispersed in a physiologically tolerable liquid carrier medium, and
generating a radar-based signal or image of at least part of said subject, said marker or contrast agent being capable on dissolution or dispersion in water of yielding a fluid having an impact on the radar radiation signal in the subject.
In the method of the invention, the step of generating a radar based signal or image of at least part of said sample (or subject) preferably comprises
a. subjecting the sample (or subject) to radar radiation;
b. detecting the radar radiation that has interacted with the sample (or subject); and
c. processing the detected radar radiation to generate an image of the sample (or subject).
Thus, viewed from another aspect, the invention relates to a method of producing an image of a sample containing a radar marker or radar contrast agent, said method comprising
a. subjecting the sample to radar radiation;
b. detecting the radar radiation that has interacted with the sample; and c. processing the detected radar radiation to generate an image of the sample.
In the method of the invention, the radar radiation is preferably emitted from a first antenna (e.g. in step a.), and detected at a second antenna (e.g. in step b.).
Preferably, an array of antennas is used, such that the signal emitted from each antenna is detected by the remaining antennas in the array.
In the method of the invention, the step of generating a radar based signal or image of at least part of said sample (or subject) preferably comprises: i. subjecting the sample (or subject) to radar radiation emitted from one or transmitters;
ii. detecting the effect of the contents of the sample (or subject) on the passage of the radar radiation through the sample (or subject) by recording two or more signals, each signal being associated with a different propagation path within the sample (or subject); and
iii. processing the detected radar radiation by aligning the signals to generate two or more aligned signals which are synthetically focused on a desired volume of the sample (or subject), and processing the aligned signals to generate part of the image of the sample (or subject).
Preferably, steps i., ii. and iii. are repeated until an image of the sample (or subject) has been generated. Medical imaging using radar is known in the art and would be familiar to the skilled person. This type of imaging is sometimes referred to as microwave imaging, or ultrawideband (UWB) microwave imaging. The range of frequencies used in radar imaging typically varies from 0.1-40 GHz, preferably 0.5-20 GHz. Step c. is typically done using a computer processor which generates an image of the sample (or subject) on a display device such as a computer screen. Algorithms to process signals detected from the one or more detecting antenna(s) are known in the art and would be familiar to the skilled person. Step c. preferably comprises generating an image of the sample (or subject) showing the distribution of the contrast agent in the sample (or subject).
The method preferably further comprises the step of administering the contrast agent to the sample (or subject).
The method preferably further comprises the step of using the image of the subject to diagnose a disease in the subject, preferably a human or non-human animal subject. The sample used in the method can be part of a human or non-human animal body, or alternatively a inanimate tissue sample which has been taken from a human or non-human animal body. Alternatively, the method may be carried out on a synthetic mimic of human or non-human animal tissue. Such synthetic analogues are typically called "phantoms" in the art.
The terms "sample" and "subject" as used herein are generally interchangeable. The term subject is however generally used when referring to animate or live samples, such as human or non-human animals which are being imaged.
The present invention also relates to an imaging apparatus comprising
a radar contrast agent;
one or more antennas capable of emitting radar radiation to a defined volume and receiving radar radiation that has passed through that volume; and a computer processor for processing the signals received by the one or more antennas to form an image of the defined volume.
Preferably, the defined volume is sized to accommodate a human body. The apparatus of the invention preferably also comprises a sample which contains the radar contrast agent, wherein at least part of the sample is located in the defined volume. Preferably, the sample is inanimate (i.e. does not form part of a living organism). The apparatus of the invention preferably also comprises a means for administering the radar contrast agent to a human or non-human animal, such as a syringe, a catheter or an enema kit.
Viewed from another aspect the invention provides the use of a physiologically tolerable agents, markers and contrast agents which are capable of changing the reflection properties of radar radiation in the human body after administration of the agent, preferably in diagnosis of a disease in a human or non-human animal. Such diagnosis is preferably by mapping of disease tissue by radar and by monitoring the signal reflected from the human or non-human animal. The present invention also relates to contrast agents for use in diagnosis of a human or nonhuman animal by radar imaging.
In the imaging methodology of the present invention, the sample is preferably not located in an external (or applied) magnetic field.
A wide range of materials can be used as markers and contrast agents for radar- based medical diagnostic methods, but particular mention should be made of five categories of contrast agent: organic iodinated agents; metal chelates, gas, magnetic iron oxide particles and inorganic salts.
Organic Iodinated Agents
Insofar as organic iodinated agents are concerned, particular mention should be made of those agents already proposed in the literature for use as X-ray contrast agents. Examples of such materials include many compounds with low toxicity and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
Examples of X-ray contrast agents suited for use according to the present invention include in particular the iodinated contrast agents, especially those containing one or more, generally one or two, triiodophenyl groups in their structure. The most preferred organic iodinated compounds to be used as markers and contrast agents for radar-based medical diagnosis are water-soluble agents comprising one or two benzene rings each substituteted with 3 iodine atoms.
The even more preferred agents are such agents without any charge in vivo; so- called non-ionic agents. These compounds have several alcohol groups to secure that the substances have high water-solubility without being a salt.
Preferred gents are the following compounds: diatrizoic acid, ioxaglinic acid, iomeprol, iobitriol, iohexol, iopamidol, iopentol, iodixanol, ioforminol, ioxaglate, ioxilan, iopromide, iotrolan, ioversol and iothalamate. The even most preferred agents are the following compounds: iohexol, iopamidol, iopentol, iodixanol, ioforminol, ioxaglate, ioxilan, iopromide, iotrolan, ioversol and iothalamate. Iohexol is the most preferred organic iodinated agent.
Particular organic iodinated compounds useful according to the invention thus, for example, include compounds described in US5,993,780 (Nycomed), US5,958,376 (Nycomed), US5,958,375 (Nycomed), US5,882,628 (Nycomed), US7,754,920 (GE Healthcare), UD7,662,859 (GE Healthcare), US7,592,482 (Bracco), US7,485,753 (GE Healthcare), US4,032,567 (Schering), US4,239,747 (Schering), US4,264,572 (Schering), US4,269,819 (Schering), US4,269,819 (Schering), US4,364,921 (Schering), US4,395,391 (Schering), US4,426,371 (Schering), US4,547,357 (Schering), US5,004,835 (Schering), US5,073,362 (Schering)US5, 183,654
(Schering), US 5,232,685 (Schering), US4, 139,605 (Bracco), US4,348,377
(Bracco), US4,352,788 (Bracco), US5.591.846 (Bracco), US5,628,980 (Bracco), US5,689,002 (Bracco), US5,856,570 (Bracco), US5,908,610 (Bracco),
US5.91 1 ,972 (Bracco), US6,350,908 (Bracco), US6,420,603 (Bracco),
US6,506,938 (bracco), US7, 115,778 (Bracco), US4,006,743 (Mallinckrodt), US4, 125,599 (Mallinckrodt), US4, 160,015 (Mallinckrodt), US4,396,598
(Mallinckrodt), US5.019,371 (Mallinckrodt), US5,075,502 (Mallinckrodt),
US5.191.120 (Mallinckrodt), US5,356,613 (Mallinckrodt), US5,204,086 (Nycomed), US5,349,085 (Nycomed), US6,406,680 (Nycomed), US6.310,243 (Nycomed) and US2010322868 (Nycomed) . The disclosures of these and all other documents cited herein are incorporated herein by reference.
As mentioned above, the organic iodinated agents used in the present invention are preferably iodobenzene compounds (i.e. having iodine as a ring substituent on an aromatic C6 ring), especially diiodo or more preferably triiodo benzene compounds, in particular diiodo and triiodo benzene compounds having the iodines at non- adjacent ring positions. The iodobenzene ring is preferably also substituted by hydrophilic groups comprising one, two or three hydroxyl groups. Preferred hydrophilic groups include
(HO)nXCONR1-, and
(HO)nXNR1CO- ,
wherein X is a Ci-6 alkylene group, especially an ethylene and more especially propylene group;
R1 is hydrogen or a methyl group; and
where n is 1 , 2, or 3, preferably 2 or 3.
The most preferred iodinated agents are;
Figure imgf000010_0001
Diatrizoic acid
Figure imgf000010_0002
loxaglinic acid
Figure imgf000010_0003
Figure imgf000011_0001
loversol
Figure imgf000011_0002
lodixanol
Figure imgf000011_0003
lomeprol
Figure imgf000011_0004
lobitriol
Metal Chelates Insofar as metal chelates are concerned, particular mention should be made of theoe agents already proposed in the literature for use as MRI contrast agents. Examples of such materials include many compounds with low toxicity and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
Examples of metal chelates suited for use according to the present invention include in particular paramagnetic chelates especially gadolinium chelates, dysprosium chelates, iron chelates and manganese chelates, especially those containing a chelating agent being an amino acid derivative like for example derivatives of EDTA, DTPA, DPDP, DOTA and D03A.
The most preferred metal chelates to be used as markers and contrast agents for radar-based medical diagnosis are water-soluble agents comprising gadolinium (3+) or manganese (2+). Both non-ionic chelates and ionic chelates are among the most preferred chelates for use as markers and contrast agents for radar-based medical diagnosis.
The even most preferred chelates are the following compounds: GdDTPA
(gadopentetate dimeglumine), GdDOTA (gadoteric acid meglumine), GdDTPA-BMA (gadodiamide), Gd2HP-D03A (gadoteridol), MnDPDP (mangafodipir),
gadoversetamide, gadobenic acid, gadoxetic acid, gadofovest, gadobutrol, gadocoletic acid, gadodenterate, gadomelitol, gadopentamide. Non-ionic chelates are used as pharmaceutically acceptable salts like sodium salt, potassium salt or meglumine salt.
The most preferred chelates are:
Figure imgf000012_0001
Gadopentetate
Figure imgf000013_0001
Ňadoversetamide
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000014_0003
Gadoxetinic acid
Particular metal chelates useful according to the invention thus, for example, include compounds described in US7.767.196 (University of Hong Kong), US7,745,590 (University of Utah), US7,368,099 (Kyushu University), US4,647,447 (Schering), US4,957,939 (Schering), US4,963,344 (Schering), US 5,021 ,236 (Schering), US5,098,692 (Schering), US5, 277,895 (Schering), US5,316,756 (Schering), US5,334,371 (Schering), US5,362,475 (Schering), US5,403,572 (Schering), US5.419,894 (Schering), US5,560,903 (Schering), US5,595,725 (Schering), US4.916,246 (Bracco), US4,980,502 (Bracco), US5, 132,409 (Bracco), US5, 182,370 (Bracco), US5,474,756 (Bracco), US5,674,470 (Bracco),
US5,846,519 (Bracco) and US5,958,373 (Nycomed Salutar). Gases
Insofar as gases are concerned, particular mention should be made of those agents already proposed in the literature for use as ultrasound contrast agents and to some extent for use as gastrointestinal X-ray contrast agents. Examples of such materials include many compounds with low toxicity, low solubility in blood and compounds may be selected which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents. Examples of gases suited for use according to the present invention include in air, sulfurhexafluoride and perfluorocarbons; for use within the vascular system gases with low solubility in blood are the most preferred gases. Perfluorocarbons such as perfluoropropane and perfluorobutane are particularly preferred. The even most preferred gases for intravascular administration are
sulfurhexafluoride, perfluoropropane and perfluorobutane, with perfluoropropane and perfluorobutane being particularly preferred. Perfluoropropane is the most preferred gas. The most preferred agents gases for intravascular administration are preferably encapsulated into surfactants, phospholipids, carbohydrates, albumin or synthetic or semisynthetic polymer materials.
The even most preferred gas-based products according to the present invention are products like SonoVue, Sonazoid, Optison and Levovist.
Encapsulated gas-based compositions useful according to the invention thus, for example, include compounds described in US 6,221 ,337 (Nycomed), US6,274,120 (Nycomed), US5,674,468 (Nycomed), US5,670, 135 (Nycomed), US5,648,062 (Nycomed), US5,637,289 (Nycomed), US5,618,514 (Nycomed), US5,614, 169 (Nycomed), US5,569,449 (Nycomed), US5,567,412 (Nycomed), US5,558,856 (Nycomed), US5,558,857 (Nycomed), US5,536,490 (Nycomed), US5,529,766 (Nycomed), US6.217,850 (Nycomed), US6, 177,061 (Nycomed), US6,165,442 (Nycomed), US6, 110,444 (Nycomed), US6,106,806 (Nycomed), US6,054, 118 (Nycomed), US5,928,626 (Nycomed), US7,083,778 (Bracco), US7,033,574
(Bracco), US6,613,306 (Bracco), US6,200,548 (Bracco), US6,187,288 (Bracco), US6, 183,725 (Bracco), US6, 139,818 (Bracco), US6, 136,293 (Bracco),
US5,846,518 (Bracco), US6, 110,443 (Bracco), US5,840,275 (Bracco),
US5,830,435 (Bracco), US5, 827,504 (Bracco), US5.71 1 ,933 (Bracco),
US5,686,060 (Bracco), US5,658,551 (Bracco), US5,643,553 (Bracco),
US5,597,549 (Bracco), US5,587, 199 (Bracco), US5,567,414 (Bracco),
US5,556,610 (Bracco), US5.531.980 (Bracco), US5,445,813 (Bracco),
US5.413,774 (Bracco), USUS5,380,519 (Bracco), US6,264,959 (Schering), US5,425,366 (Schering), US6, 146,657 (ImaRx), US6,315,981 (ImaRx), US6,479,034 (Bristol-Myers Squibb), US6,528,039 (Bristol-Myers Squibb), US6,548,047 (Bristol- Myers Squibb), US6.551.576 (Bristol-Myers Squibb), US6,680,047 (Amersham Health), US6,7, 16,412 (ImaRx), US6,998,107 (Bristol-Myers Squibb), US5.141.738 (Schering), US5,352,436 (Drexel University), US5, 536,490 (Nycomed),
US5,573,751 (Sonus), US5,585,1 12 (ImaRx), US5,614, 169 (Nycomed),
US5,656,211 (ImaRx), US6,045,777(Acuphere), US7,374,745 (Mallinckrodt) and US7,892,522 (GE Healthcare).
Magnetic Iron Oxide Insofar as magnetic iron oxides are concerned, particular mention should be made of those agents already proposed in the literature for use as MRI contrast agents. Examples of such materials include any particulate ferromagnetic or
superparamagnetic material which distribute preferentially within the body, e.g. which congregate at particular tissues, organs or tissue abnormalities or which are essentially confined to the circulatory system and act as blood pool agents.
Examples of magnetic iron oxides suited for use according to the present invention include any particulate iron oxide like magnetite (Fe304) or gamma-iron(lll)oxide. Both the particle size and the size of the iron oxide crystals might vary over a large range from a few nanometers to micrometers. The iron oxide material might be encapsulated or coated with various organic materials like for example natural polymers, synthetic polymers, proteins, carbohydrates, polyethyleneglycols and other materials.
The even most preferred magnetic iron oxide-based products according to the present invention are products like Endorem (Feridex), Resovist, Sinerem, Combidex and Cliavist.
Iron oxide based compositions useful according to the invention thus, for example, include compounds described in US6, 123,920 (Nycomed), US5,545,395 (Bracco), US7,807,137 (University of Puerto Rico), US4,452,773 (Advanced Magnetics), US4,770,183 (Advanced Magnetics), US4,827,945 (Advanced Magnetics), US5, 102,652 (Advanced Magnetics), US5, 160,726 (Advanced Magnetics),
US5,262,176 (Advanced Magnetics), US5,204,457 (Meito Sangyo), US6, 165,378 (Meito Sangyo), US7.871.597 (AMAG) and US7.892.520 (Hong Kong University).
Inorganic salts
Insofar as inorganic salts are concerned, particular mention should be made of those agents already proposed in the literature for use as X-ray contrast agents. Examples of such materials include any particulate insoluble material like for example barium sulphate. Inorganic salts are preferably administered directly into the gastrointestinal system by oral administration or by use of an enema
Barium salts are particularly preferred inorganic salts, with barium sulphate being the most preferred. One further aspect of the present invention relates to use of liposome markers or as contrast agent in radar-based medical imaging. Liposomes are for example described in US6.217,849 (Bracco), US5,980,937 (Bracco), US5,702,722 (Bracco), US5,676,928 (Nycomed), US7,588,751 (Konica Minolta) and US7,785,568 (Marval Biosciences). One further aspect of the present invention relates to use of targeted markers or as contrast agent in radar-based medical imaging. Targeted markers and contrast agents are for example described in US6,051 ,207 (Nycomed), US6,264,917 (Nycomed), US5,414, 114 (Bracco), US6, 139,819 (lmaRx),US6,261 ,537
(Nycomed), US6.261 ,537 (Nycomed), US6.331 ,289 (Nycomed), US6.521 ,21 1 (Bristol-Myers Squibb), US7, 182,934 (GE Healhcare) and US7.413,727 (GE Healthcare).
Particularly preferred contrast agents have a Fresnel reflection coefficient of at least 0.15, more preferably at least 0.20, at frequencies of between 0.5 and 20 GHz (e.g. 5 GHz) with reference to healthy human blood as measured using a Agilent Network Analyzer N5245A at concentrations of 300 mg/ml.
By "healthy human blood" is meant blood that has recently been taken from a healthy human adult in which all blood markers such as platelet count, ion levels etc are within what would generally be deemed to be normal levels by a physician.
Particulate contrast agents for parenteral administration should preferably have particle sizes of no more than 1.5 micrometer, especially 1.0 micrometer or less.
Enteral administration of markers and contrast agents for radar based medical diagnosis including radar based medical imaging will preferably be by oral administration of the marker or contrast agent or by administration of the marker or contrast agent using an enema.
Parenteral administration of contrast agents according to the invention will generally be by injection or infusion, especially into the cardiovascular system. However the markers or contrast media may also be administered into body cavities having external voidance ducts, e.g. by catheter into the bladder, uterus etc.
The dosages of markers and contrast agents for radar-based medical diagnosis used according to the invention will vary over a broad range depending on a variety of factors such as administration route, the pharmacodynamic properties of the contrast agent (the more widely distributing the agent is the larger the dose may be), the chemical and physical nature of the contrast agent, and the frequency of the electrical current applied in the impedance measurement.
Typically however agents will be administered in concentrations of 1 micromol/l to 1 mol/l, preferably 0.01 to 0.8 mmol/l and dosages will lie in the range 0.002 to 20 mmol/kg bodyweight, generally 0.005 to 10 mmol/kg. The overall dosage will generally be 1 to 200 ml when administered into the cardiovascular system or 5 ml to 1.5 litres of marker or contrast agent when administered into a body cavity having an external voidance duct, e.g. by oral or rectal administration. The markers and contrast agents according to the present invention may be used for a wide range of clinical indications with appropriate selection of the contrast agent (for its pharmacodynamic properties) and of the administration route. Thus non-absorbable markers and contrast agents for radar-based medical diagnosis are particularly useful in the gastrointestinal tract, for diagnosis of abnormalities therein or as markers of the gastrointestinal system. Such agents may also be used for dynamic studies, for example of gastric emptying. In studies of the gastrointestinal tract, it may be advisable to use a pH control agent such as cimetidine to suppress naturally occuring pH variations which might otherwise reduce imaging accuracy. Some of the marker and contrast agents are absorbable from the gastrointestinal trace and may be taken up by the liver and excreted into the bile. Such agents can thus be used for imaging the hepatobiliary system and for liver function studies even following oral rather than parenteral administration. The clinical indications for parenteral markers for contrast agents include CNS examination, perfusion studies, blood pool imaging, examination of body cavities, of the pelvic region and of the kidneys, hepatobiliary studies and studies of liver and kidney function, tumour imaging, and diagnosis of infarcts, especially in the heart. As a further alternative means of improving radar-based diagnosis, also within the scope of the invention, contrast may be enhanced by administration of a
physiologically active agent which serves to modify body fluid distribution, e.g. a diuretic, thereby causing image modification in body areas where body fluid is increased or decreased. Preferred methods and uses described above utilise the preferred contrast agents mentioned herein.
Where the invention relates to a method of diagnosis or use in diagnosis, preferred diseases are those diseases mentioned herein, such as diseases selected from abnormalities in the gastrointestinal tract, cancer and tumours such as for example breast cancer, lung cancer, liver cancer, metastisis, brain cancer and colorectal cancer; and infarcts or other cardiovascular diseases or cardiovascular events such as in the heart infarcts.
The invention will now be illustrated further by means of the following non-limiting Examples:
Example 1 lodinated marker and contrast agent for radar-based diagnosis including imaging
A solution of iohexol (Omnipaque) (300 mg /ml, 50 ml) is administered
intravenously to a patient. The patient undergoes a radar-based diagnosis of the heart and the kidneys.
Example 2
Gas-based marker and contrast agent for radar-based diagnosis including imaging
A suspension of encapsulated perfluoropropane (Optison) (0.19 mg/ml, 3 ml) is administered intravenously to a patient. The patient undergoes a radar-based diagnosis of the cardiovascular system. Example 3
Metal chelate marker and contrast agent for radar-based diagnosis including imaging
GdDTPA bis-meglumine salt (Magnevist) (0.5 mmol/ml), 16 ml) is administered intravenouly to a patient. The patient undergoes a radar-based diagnosis of the heart, brain and the renal system. Example 4
Magnetic iron oxide-based marker and contrast agent for radar-based diagnosis including imaging Magnetic iron oxide particles (Resovist) (0.25 mmol/ml, 10 ml) is administered intravenously to a patient. The patient undergoes a radar-based diagnosis of the cardiovascular system.
Example 5
Inorganic salt marker and contrast agent for radar-based diagnosis including imaging
Barium sulphate (Mixobar) (1 gram/ml, 400 ml) is administered as an enema to a patient. The patient undergoes a radar-based diagnosis of abdomen.
Example 6
Measurement of permittivity (medical radar contrast parameter) of various undiluted contrast agents and distilled water.
One important contrast parameter in medical radar imaging is the permittivity. The permittivity is a measure of how the electrical field is affected by or affects the medium. The permittivity in various contrast agents was determined using Agilent Network Analyzer N5245A with Agilent 5070E dielectric probe kit. (Agilent Technologies, USA).
The contrast agents were the following:
Particulate x-ray contrast agent: Barium sulfate suspension: 40% w/v (30% v/v) (Tagitol-V (E-Z-EM, Canada)).
Ionic iodinated X-ray contrast agent: 270 mg l/ml (diatrizoate sodium 100 mg/ml and diatrizoate meglumine 600 mg/ml, Gastrografin (Bayer Schering Pharma, Germany))
Non-ionic iodinated X-ray contrast agent : 350 mgl/ml (iohexol.( Omnipaque. GE Healthcare, USA))
Paramagnetic gadolinium based chelate: 334mg/ml (gadobenic acid (Multihance, Bracco, Italy))
The permittivity data on undiluted contrast agents and distilled water with reference values on whole blood are shown in Figure 1 and Figure 2
Example 7
Measurement of conductivity (medical radar contrast parameter) of various undiluted contrast agents and distilled water.
One important contrast parameter in medical radar imaging is the conductivity. The conductivity in various contrast agents was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The contrast agents are described in Example 6.
The conductivity data on undiluted contrast agents and distilled water with reference values on whole blood are shown in Figure 3 and Figure 4. Example 8
Measurement of permittivity (medical radar contrast parameter) of diluted Multihance.
The permittivity in dilued Multihance was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The permittivity data on diluted Multihance are shown in Figure 4 and Figure 6.
Example 9
Measurement of conductivity (medical radar contrast parameter) of diluted Multihance. The conductivity of diluted Multihance was determined using Agilent Network
Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The conductivity data on diluted Multihance are shown in Figure 7 and Figure 8. Example 10
Measurement of permittivity (medical radar contrast parameter) of diluted Gastrografin.
The permittivity in dilued Gastrografin was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The permittivity data on diluted Gastrografin are shown in Figure 9 and Figure 10. Example 11
Measurement of conductivity (medical radar contrast parameter) of diluted Gastrografin.
The conductivity of diluted Gastrografin was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA). The conductivity data on diluted Gastrografin are shown in Figure 1 1 and Figure 12. Example 12
Measurement of permittivity (medical radar contrast parameter) of diluted Omnipaque.
The permittivity in dilued Omnipaque was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The permittivity data on diluted Omnipaque are shown in Figure 13 and Figure 14. Example 13
Measurement of conductivity (medical radar contrast parameter) of diluted Omnipaque.
The conductivity of diluted Omnipaque was determined using Agilent Network Analyzer N5245A with Agilent (5070E dielectric probe kit.(Agilent Technologies, USA).
The conductivity data on diluted Omnipaque are shown in Figure 15 and Figure 16.
Example 14
Calculation of Fresnel reflection coefficient for undiluted contrast agent versus blood The Fresnel reflection coefficient versus blood is calculated and shown in Figure 17 and Figure 18.
Omnipaque (iohexol) shows a surprisingly high Fresnel reflection coefficient. Example 15
Calculation of Fresnel reflection coefficient for undiluted contrast agent versus muscle
The Fresnel reflection coefficient versus muscle is calculated and shown in Figure 19 and Figure 20.
1. Omnipaque (iohexol) shows a surprisingly high Fresnel reflection coefficient.

Claims

Claims
1. A method of imaging a sample comprising a radar marker or radar contrast agent, said method comprising:
generating a radar-based signal or image of at least part of said sample, said marker or contrast agent being capable on dissolution or dispersion in water of yielding a fluid having an impact on the radar radiation signal in the sample.
2. The method as claimed in claim 1 wherein said marker or contrast agent is selected from organic iodinated agents, metal chelates, gas, magnetic iron oxide particles or inorganic salts.
3. The method as claimed in claim 1 wherein said contrast agent comprises organic iodinated agents.
4. The method as claimed in claim 3, wherein said organic iodinated agent is non-ionic.
5. The method as claim in claim 4, wherein said organic iodinated agent is selected from the group consisting of iohexol, iopamidol, iopentol, iodixanol, ioforminol, ioxaglate, ioxilan, iopromide, iotrolan, ioversol and iothalamate.
6. The method as claimed in claim 1 wherein said contrast agent comprises metal chelates.
7. The method as claimed in claim 6, wherein said metal chelates are selected from the group consisting of gadolinium chelates, dysprosium chelates, iron chelates and manganese chelates.
8. The method as claimed in claim 1 wherein said contrast agent comprises gas.
9. The method as claimed in claim 8, wherein the gas is selected from the group consisting of air, sulfurhexafluoride and perfluorocarbons, preferably perfluoropropane and perfluorobutane.
10. The method as claimed in claim 1 wherein said contrast agent comprises magnetic iron oxide.
1 1. The method as claimed in claim 1 wherein said contrast agent comprises an inorganic salt, preferably a barium salt such as barium sulphate.
12. The method of any preceding claim, wherein the sample is a human or non- human animal subject.
13. The method of any preceding claim, further comprising the step of administering the radar marker or radar contrast agent to said sample.
14. The method of claim 13, wherein the marker or contrast agent is dissolved or dispersed in a physiologically tolerable liquid carrier medium.
15. The method of any of claims 12-14, wherein the marker or contrast agent is administered parenterally to the human or non-human animal subject, preferably by injection or infusion.
16. The method of any of claims 12-14, wherein the marker or contrast agent is administered enterally to the human or non-human animal subject, preferably by oral administration or using an enema.
17. The method of any preceding claim, wherein the step of generating a radar based signal or image of at least part of said sample comprises
a. subjecting the sample to radar radiation;
b. detecting the radar radiation that has interacted with the sample; and c. processing the detected radar radiation to generate an image of the sample.
18. The method of any of claims 12-17, further comprising using the image of the sample to diagnose a disease in the human or non-human animal subject.
19. Use of a radar contrast agent as defined in any of claims 2-1 1 for medical diagnosis based on radar technology.
20. A contrast agent as defined in any of claims 2-1 1 for use in medical
diagnosis based on radar technology.
21. The method, use or contrast agent of any of claims 18-20, wherein the
diagnosis is of abnormalities in the gastrointestinal tract; cancer and tumours such as for example breast cancer, lung cancer, prostate cancer, stomach cancer, liver cancer, metastasis, brain cancer and colorectal cancer; or infarcts or other cardiovascular diseases or cardiovascular events such as in the heart infarcts.
22. Use of a radar contrast agent as defined in any of claims 2-11 in medical imaging based on radar radiation.
23. An imaging apparatus comprising
a radar contrast agent;
one or more antennas capable of emitting radar radiation to a defined volume and receiving radar radiation that has passed through that volume; and a computer processor for processing the signals received by the one or more antennas to form an image of the defined volume.
24. The apparatus of claim 23, wherein the radar contrast agent is as defined in any of claims 2-1 1.
25. The apparatus of claim 23 or claim 24, wherein the defined volume is sized to accommodate a human body.
26. The apparatus of any of claims 23-25 further comprising a means for
administering the radar contrast agent to a human or non-human animal, preferably a syringe, catheter or enema kit.
PCT/EP2012/056363 2011-04-07 2012-04-05 Agents for medical radar diagnosis WO2012136813A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20110544 2011-04-07
NO20110544 2011-04-07

Publications (3)

Publication Number Publication Date
WO2012136813A2 true WO2012136813A2 (en) 2012-10-11
WO2012136813A3 WO2012136813A3 (en) 2013-01-17
WO2012136813A9 WO2012136813A9 (en) 2013-03-14

Family

ID=45998277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/056363 WO2012136813A2 (en) 2011-04-07 2012-04-05 Agents for medical radar diagnosis

Country Status (1)

Country Link
WO (1) WO2012136813A2 (en)

Citations (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006743A (en) 1973-01-15 1977-02-08 The Johns Hopkins University System for continuous withdrawal of blood
US4032567A (en) 1972-02-16 1977-06-28 Schering Aktiengesellschaft Triiodoisophthalic acid monoamino acid amides, process for the preparation thereof, and use thereof as x-ray contrast media
US4125599A (en) 1976-08-19 1978-11-14 Mallinckrodt, Inc. X-ray contrast agents
US4139605A (en) 1977-03-28 1979-02-13 Bracco Industria Chimica S.P.A. Water-soluble, non-ionizing, radiopaque compounds and contrast compositions containing the same
US4239747A (en) 1976-06-23 1980-12-16 Schering Aktiengesellschaft Dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) useful as x-ray contrast agents
US4264572A (en) 1978-11-30 1981-04-28 Schering Aktiengesellschaft X-ray contrast media
US4269819A (en) 1978-07-14 1981-05-26 Schering Aktiengesellschaft 2,4,6-Triiodobenzonitrile derivatives and X-ray contrast media comprising them
US4348377A (en) 1979-08-09 1982-09-07 Bracco Industria Chimica S.P.A. New derivatives of 2,4,6-triiodo-isophthalic acid, proceses for their synthesis and X-ray contrasting materials containing these
US4352788A (en) 1979-08-09 1982-10-05 Bracco Industria Chimica S.P.A. Derivatives of 2,4,6-triiodo-isophthalic acid, processes for their synthesis and X-ray contrasting materials containing these
US4364921A (en) 1979-03-08 1982-12-21 Schering, Aktiengesellschaft Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media
US4395391A (en) 1980-11-25 1983-07-26 Schering Aktiengesellschaft Unsymmetrically substituted dicarboxylic-acid-bis-(2,4,6-triiodo-anilides), their preparation, and x-ray contrast media containing same
US4396598A (en) 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
US4426371A (en) 1980-10-10 1984-01-17 Schering, Aktiengesellschaft Novel N-hydroxyalkylated dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides), as X-ray contrast media
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4547357A (en) 1981-12-18 1985-10-15 Schering, Aktiengesellschaft N-Hydroxyethylated 2,4,6-triiodoaminoisophthalic acid bistrihydroxybutylamides, their preparation and x-ray contrast media containing them
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4916246A (en) 1986-01-30 1990-04-10 Bracco Chimica S.P.A. Paramagnetic chelates useful for NMR imaging
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5004835A (en) 1987-11-16 1991-04-02 Schering Aktiengesellschaft Substituted dicarboxylic acid-bis(3,5-dicarbamoyl-2,4,6-triiodoanilides), process for their production as well as X-ray contrast media containing them
US5019371A (en) 1990-11-21 1991-05-28 Mallinckrodt Medical, Inc. Novel x-ray contrast agents, compositions and methods
US5030956A (en) 1989-04-25 1991-07-09 Murphy Quentin M Radar tomography
US5073362A (en) 1987-09-17 1991-12-17 Schering Aktiengesellschaft Dicarboxylic acid-bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) and x-ray contrast media containing them
US5075502A (en) 1989-12-13 1991-12-24 Mallinckrodt, Inc. Nonionic x-ray contrast agents, compositions and methods
US5098692A (en) 1986-11-28 1992-03-24 Schering Aktiengellschaft Calcium chelate and gadolinium pharmaceutical composition and methods of x-ray and nmr imaging
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US5183654A (en) 1989-11-03 1993-02-02 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
US5191120A (en) 1989-12-13 1993-03-02 Mallinckrodt Medical, Inc. Process for preparing nonionic X-ray contrast agents
US5204457A (en) 1989-10-20 1993-04-20 Meito Sangyo Kabushiki Kaisha Organic magnetic complex
US5204086A (en) 1982-10-01 1993-04-20 Nycomed Imaging As X-ray contrast agent
US5232685A (en) 1989-11-03 1993-08-03 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5277895A (en) 1990-11-08 1994-01-11 Schering Aktiengesellschaft Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives, process for their production and pharmaceutical agents containing these derivatives
US5316756A (en) 1983-07-01 1994-05-31 Schering Aktiengesellschaft NMR imaging using paramagnetic chelates having hydroxyalkyl-substituted amide groups
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5349085A (en) 1982-11-08 1994-09-20 Nycomed Imaging As X-ray contrast agents
US5352436A (en) 1992-11-02 1994-10-04 Drexel University Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same
US5356613A (en) 1991-03-18 1994-10-18 Mallinckrodt Medical, Inc. X-ray contrast agents, compositions and methods
US5380519A (en) 1990-04-02 1995-01-10 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5413774A (en) 1992-01-23 1995-05-09 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5414114A (en) 1991-07-22 1995-05-09 Bracco International B.V. Method for making conjugate moieties capable of chelating paramagnetic metals and designed for coupling with a factor responsive to specific cellular marker sites
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5474756A (en) 1986-01-23 1995-12-12 Bracco International B.V. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5529766A (en) 1991-03-28 1996-06-25 Nycomed Imaging As Contrast agents
US5536490A (en) 1991-03-28 1996-07-16 Nycomed Imaging As Contrast agents
US5545395A (en) 1992-08-13 1996-08-13 Bracco Research, S.A. Method of imaging using encapsulated magnetite particles
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5558857A (en) 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
US5558856A (en) 1992-01-09 1996-09-24 Nycomed Imaging As Microbubble-generating contrast agents for ultrasound and magnetic resonance imaging
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US5567412A (en) 1992-01-09 1996-10-22 Nycomed Imaging As Contrast agents consisting of galactose particles and an amphilic carboxylic acid
US5573751A (en) 1991-09-17 1996-11-12 Sonus Pharmaceuticals, Inc. Persistent gaseous bubbles as ultrasound contrast media
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5591846A (en) 1989-11-29 1997-01-07 Bracco International B.V. Nonionic radiographic contrast agents
US5618514A (en) 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
US5648062A (en) 1992-01-09 1997-07-15 Nycomed Imaging As Contrast agents consisting of galactose particles
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5676928A (en) 1994-03-28 1997-10-14 Nycomed Imaging As Liposomes
US5689002A (en) 1995-09-08 1997-11-18 Bracco International B.V. Process for the crystallization from water of (S)-N,N'-bis 2-hydroxy-1-(hydroxymethyl)ethyl!-5- 2-hydroxy-1-oxopropyl)amino!-2,4,6-triiodo-1,3-benzendicarboxamide
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
US5711933A (en) 1990-05-18 1998-01-27 Bracco International B.V. Method of making polymeric gas or air filled microballoons for ultrasonic echography
US5827504A (en) 1994-12-16 1998-10-27 Bracco Research S.A. Method of echographic imaging using frozen gasbubble suspensions
US5846518A (en) 1992-12-16 1998-12-08 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media contrast agents containing the media and method
US5856570A (en) 1994-11-29 1999-01-05 Bracco International B.V. Process for preparing 5-amino-2,4,6-triiodoisophthalic acid dichloride by chlorination of the corresponding acid in the presence of a tertiary amine salt or quaternary ammonium salt
US5882628A (en) 1994-09-23 1999-03-16 Nycomed Imaging As Contrast media
US5928626A (en) 1992-01-09 1999-07-27 Nycomed Imaging As Contrast agents, consisting of carbohydrate particles
US5958375A (en) 1994-09-23 1999-09-28 Nycomed Imaging As Urea-linked, iodinated bis phenyl compounds for X-ray contrast media
US5958373A (en) 1993-09-07 1999-09-28 Nycomed Salutar Inc. Polychelants as contrast enhancing agents
US6045777A (en) 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6051207A (en) 1996-10-28 2000-04-18 Nycomed Imaging As Contrast agents
US6054118A (en) 1997-01-22 2000-04-25 Nycomed Imaging As Contrast agents comprising two types of gas-containing microparticles
US6110444A (en) 1994-03-01 2000-08-29 Nycomed Imaging As Gas-containing microcapsules useful as contrast agents for diagnostic imaging
US6123920A (en) 1996-01-10 2000-09-26 Nycomed Imaging As Superparamagnetic contrast media coated with starch and polyalkylene oxides
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6165378A (en) 1996-08-30 2000-12-26 Meito Sangyo Kabushiki Kaisha Polysaccharide derivative/magnetic metal oxide composite
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
US6177061B1 (en) 1997-04-23 2001-01-23 Nycomed Imaging As Contrast agents comprising an azeotropic mixture of two gases for ultrasound investigations
US6217850B1 (en) 1995-06-07 2001-04-17 Nycomed Imaging As Method of making lyophilized microbubble compositions useful as contrast agents
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US6221337B1 (en) 1996-02-19 2001-04-24 Nycomed Imaging As Microbubbles surrounded by a monolayer of negatively charged phospholipids as contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6264959B1 (en) 1988-02-05 2001-07-24 Schering Aktiengesellschaft Ultrasonic contrast agents, process for their preparation and their use as a diagnostic and therapeutic agent
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US6274120B1 (en) 1994-02-15 2001-08-14 Nycomed Imaging As Dry microparticles for use as a contrast agent
US6310243B1 (en) 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US6315981B1 (en) 1989-12-22 2001-11-13 Imarx Therapeutics, Inc. Gas filled microspheres as magnetic resonance imaging contrast agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6350908B1 (en) 1998-09-11 2002-02-26 Bracco Imaging S.P.A Process for the preparation of S-N,N′-bis [2-hydroxy-1-(hydroxymethyl) ethyl]-5- [(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
US6406680B1 (en) 1999-09-17 2002-06-18 Nycomed Imaging As X-ray contrast agents
US6420603B1 (en) 1998-11-27 2002-07-16 Bracco International B.V. Process for the preparation of n,n'-bis[2,3-dihydroxypropyl]-5-[(hydroxyacetyl) methylamino]-2, 4,6-triiodo-1, 3-benzenedi carboxamide
US6506938B1 (en) 1993-07-30 2003-01-14 Bracco International B.V. Process for the purifying of iopamidol
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6528039B2 (en) 1991-04-05 2003-03-04 Bristol-Myers Squibb Medical Imaging, Inc. Low density microspheres and their use as contrast agents for computed tomography and in other applications
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040019282A1 (en) 2002-07-29 2004-01-29 Mullen Linda J. Hybrid lidar-radar for medical diagnostics
US20040249257A1 (en) 2003-06-04 2004-12-09 Tupin Joe Paul Article of manufacture for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US7115778B2 (en) 1999-02-26 2006-10-03 Bracco Imaging, S.P.A. Process for the preparation of iopamidol
US7182934B2 (en) 1996-10-28 2007-02-27 Ge Healthcare As Contrast agents
US7368099B2 (en) 2003-02-27 2008-05-06 Kyushu University, National University Corporation MRI contrast agents
US7374745B2 (en) 1998-10-12 2008-05-20 Mallinckrodt, Inc. Ultrasound contrast agents
US7413727B2 (en) 1997-04-24 2008-08-19 Ge Healthcare As Contrast agents
US7485753B2 (en) 2005-12-02 2009-02-03 Ge Healthcare As Contrast agents
US20090192384A1 (en) 2008-01-30 2009-07-30 Siemens Aktiengesellschaft Medical unit and method for improving examination and treatment workflows
US7588751B2 (en) 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
US7592482B2 (en) 2005-09-13 2009-09-22 Bracco Imaging S.P.A. Process for the preparation of contrast agents
US7745590B1 (en) 2001-11-13 2010-06-29 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
US7754920B1 (en) 2009-07-21 2010-07-13 Ge Healthcare As Solvent reduction in crystallisation of intermediate for non-ionic X-ray contrast agents
US7767196B2 (en) 2005-11-21 2010-08-03 The University Of Hong Kong Optimized relaxivity and specificity hepatobiliary MRI contrast agent
US7785568B2 (en) 2004-04-21 2010-08-31 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
WO2010124117A2 (en) 2009-04-22 2010-10-28 Lifewave, Inc. Fetal monitoring device and methods
US20100292559A1 (en) 2009-05-14 2010-11-18 Thilo Hannemann Radar-equipped patient bed for a medical imaging apparatus, and operating method therefor
US20100322868A1 (en) 2007-07-12 2010-12-23 Mikkel Thaning Contrast agents
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7892520B2 (en) 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
US7892522B2 (en) 1996-08-02 2011-02-22 Ge Healthcare As Contrast agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712524D0 (en) * 1997-06-16 1997-08-20 Nycomed Imaging As Method
DE102008064400A1 (en) * 2008-06-02 2009-12-03 Rohde & Schwarz Gmbh & Co. Kg Microwave examination with a contrast agent
GB0920839D0 (en) * 2009-11-27 2010-01-13 Univ Bristol Contrast agents for medical imaging

Patent Citations (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032567A (en) 1972-02-16 1977-06-28 Schering Aktiengesellschaft Triiodoisophthalic acid monoamino acid amides, process for the preparation thereof, and use thereof as x-ray contrast media
US4006743A (en) 1973-01-15 1977-02-08 The Johns Hopkins University System for continuous withdrawal of blood
US4239747A (en) 1976-06-23 1980-12-16 Schering Aktiengesellschaft Dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) useful as x-ray contrast agents
US4125599A (en) 1976-08-19 1978-11-14 Mallinckrodt, Inc. X-ray contrast agents
US4160015A (en) 1976-08-19 1979-07-03 Mallinckrodt, Inc. 2,4,6-Triiodobenzoic acid derivatives and their use as x-ray contrast agents
US4139605A (en) 1977-03-28 1979-02-13 Bracco Industria Chimica S.P.A. Water-soluble, non-ionizing, radiopaque compounds and contrast compositions containing the same
US4269819A (en) 1978-07-14 1981-05-26 Schering Aktiengesellschaft 2,4,6-Triiodobenzonitrile derivatives and X-ray contrast media comprising them
US4264572A (en) 1978-11-30 1981-04-28 Schering Aktiengesellschaft X-ray contrast media
US4364921A (en) 1979-03-08 1982-12-21 Schering, Aktiengesellschaft Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media
US4348377A (en) 1979-08-09 1982-09-07 Bracco Industria Chimica S.P.A. New derivatives of 2,4,6-triiodo-isophthalic acid, proceses for their synthesis and X-ray contrasting materials containing these
US4352788A (en) 1979-08-09 1982-10-05 Bracco Industria Chimica S.P.A. Derivatives of 2,4,6-triiodo-isophthalic acid, processes for their synthesis and X-ray contrasting materials containing these
US4426371A (en) 1980-10-10 1984-01-17 Schering, Aktiengesellschaft Novel N-hydroxyalkylated dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides), as X-ray contrast media
US4395391A (en) 1980-11-25 1983-07-26 Schering Aktiengesellschaft Unsymmetrically substituted dicarboxylic-acid-bis-(2,4,6-triiodo-anilides), their preparation, and x-ray contrast media containing same
US4963344A (en) 1981-07-24 1990-10-16 Schering Aktiengesellschaft Method to enhance NMR imaging using chelated paramagnetic ions
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4963344B1 (en) 1981-07-24 1992-08-25 Schering Ag
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5362475A (en) 1981-07-24 1994-11-08 Schering Aktiengesellschaft Gadolinium chelates for magnetic resonance imaging
US5595725A (en) 1981-07-24 1997-01-21 Schering Aktiengesellschaft Diagnostic media
US5021236A (en) 1981-07-24 1991-06-04 Schering Aktiengesellschaft Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules
US4547357A (en) 1981-12-18 1985-10-15 Schering, Aktiengesellschaft N-Hydroxyethylated 2,4,6-triiodoaminoisophthalic acid bistrihydroxybutylamides, their preparation and x-ray contrast media containing them
US4396598A (en) 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5204086A (en) 1982-10-01 1993-04-20 Nycomed Imaging As X-ray contrast agent
US5349085A (en) 1982-11-08 1994-09-20 Nycomed Imaging As X-ray contrast agents
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5316756A (en) 1983-07-01 1994-05-31 Schering Aktiengesellschaft NMR imaging using paramagnetic chelates having hydroxyalkyl-substituted amide groups
US5419894A (en) 1983-07-01 1995-05-30 Schering Aktiengesellschaft Complexing agents, complexes and complex salts
US5618514A (en) 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
US5670135A (en) 1983-12-21 1997-09-23 Nycomed Imaging As Ultrasonic contrast agent comprising carbohydrate particles
US5674470A (en) 1986-01-23 1997-10-07 Bracco Diagnostics Inc. Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5474756A (en) 1986-01-23 1995-12-12 Bracco International B.V. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5846519A (en) 1986-01-23 1998-12-08 Bracco Diagnostics Inc. Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US4980502A (en) 1986-01-30 1990-12-25 Bracco Industria Chimica, S.P.A. Paramagnetic chelates
US5182370A (en) 1986-01-30 1993-01-26 Bracco Industria Chimica S.P.A. Paramagnetic chelates
US4916246A (en) 1986-01-30 1990-04-10 Bracco Chimica S.P.A. Paramagnetic chelates useful for NMR imaging
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5098692A (en) 1986-11-28 1992-03-24 Schering Aktiengellschaft Calcium chelate and gadolinium pharmaceutical composition and methods of x-ray and nmr imaging
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5073362A (en) 1987-09-17 1991-12-17 Schering Aktiengesellschaft Dicarboxylic acid-bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) and x-ray contrast media containing them
US5004835A (en) 1987-11-16 1991-04-02 Schering Aktiengesellschaft Substituted dicarboxylic acid-bis(3,5-dicarbamoyl-2,4,6-triiodoanilides), process for their production as well as X-ray contrast media containing them
US6264959B1 (en) 1988-02-05 2001-07-24 Schering Aktiengesellschaft Ultrasonic contrast agents, process for their preparation and their use as a diagnostic and therapeutic agent
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5403572A (en) 1988-07-20 1995-04-04 Schering Aktiengesellschaft Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them
US5030956A (en) 1989-04-25 1991-07-09 Murphy Quentin M Radar tomography
US5204457A (en) 1989-10-20 1993-04-20 Meito Sangyo Kabushiki Kaisha Organic magnetic complex
US5183654A (en) 1989-11-03 1993-02-02 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
US5232685A (en) 1989-11-03 1993-08-03 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
US5628980A (en) 1989-11-29 1997-05-13 Bracco International B.V. Nonionic radiographic contrast agents
US5591846A (en) 1989-11-29 1997-01-07 Bracco International B.V. Nonionic radiographic contrast agents
US5191120A (en) 1989-12-13 1993-03-02 Mallinckrodt Medical, Inc. Process for preparing nonionic X-ray contrast agents
US5075502A (en) 1989-12-13 1991-12-24 Mallinckrodt, Inc. Nonionic x-ray contrast agents, compositions and methods
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6315981B1 (en) 1989-12-22 2001-11-13 Imarx Therapeutics, Inc. Gas filled microspheres as magnetic resonance imaging contrast agents
US6479034B1 (en) 1989-12-22 2002-11-12 Bristol-Myers Squibb Medical Imaging, Inc. Method of preparing gas and gaseous precursor-filled microspheres
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US5531980A (en) 1990-04-02 1996-07-02 Bracco International Bv Stable microbubbles suspensions injectable into living organisms
US7033574B1 (en) 1990-04-02 2006-04-25 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5911972A (en) 1990-04-02 1999-06-15 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5658551A (en) 1990-04-02 1997-08-19 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6110443A (en) 1990-04-02 2000-08-29 Bracco International N.V. Dry stable formation to produce microbubble suspension for ultrasound
US5643553A (en) 1990-04-02 1997-07-01 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US5380519A (en) 1990-04-02 1995-01-10 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US6136293A (en) 1990-04-02 2000-10-24 Bracco International B.V. Stable microbubbles suspensions containing saturated lamellar phospholipids
US5567414A (en) 1990-04-02 1996-10-22 Bracco International B.V. Stable microbubbles suspensions injectable into living organisms
US6139818A (en) 1990-05-18 2000-10-31 Bracco International B.V. Method of making ultrasonic contrast agent
US6200548B1 (en) 1990-05-18 2001-03-13 Bracco International B.V. Gas or air filled polymeric microballoons
US5711933A (en) 1990-05-18 1998-01-27 Bracco International B.V. Method of making polymeric gas or air filled microballoons for ultrasonic echography
US5840275A (en) 1990-05-18 1998-11-24 Bracco International B.V. Ultrasonic contrast agent with polymeric gas or air filled microballoons
US5277895A (en) 1990-11-08 1994-01-11 Schering Aktiengesellschaft Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives, process for their production and pharmaceutical agents containing these derivatives
US5019371A (en) 1990-11-21 1991-05-28 Mallinckrodt Medical, Inc. Novel x-ray contrast agents, compositions and methods
US5356613A (en) 1991-03-18 1994-10-18 Mallinckrodt Medical, Inc. X-ray contrast agents, compositions and methods
US5529766A (en) 1991-03-28 1996-06-25 Nycomed Imaging As Contrast agents
US5529766C1 (en) 1991-03-28 2002-06-04 Nycomed Imaging As Contrast agents
US5536490A (en) 1991-03-28 1996-07-16 Nycomed Imaging As Contrast agents
US6106806A (en) 1991-03-28 2000-08-22 Nycomed Imaging As Microbubble-containing contrast agents having a non-proteinaceous crosslinked or polymerised amphiphilic shell
US6998107B2 (en) 1991-04-05 2006-02-14 Bristol-Myers Squibb Pharma Comapany Composition comprising low density microspheres
US6528039B2 (en) 1991-04-05 2003-03-04 Bristol-Myers Squibb Medical Imaging, Inc. Low density microspheres and their use as contrast agents for computed tomography and in other applications
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5569449A (en) 1991-06-03 1996-10-29 Nycomed Imaging As Gaseous microparticles as ultrasound contrast agents
US5558857A (en) 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
US5414114A (en) 1991-07-22 1995-05-09 Bracco International B.V. Method for making conjugate moieties capable of chelating paramagnetic metals and designed for coupling with a factor responsive to specific cellular marker sites
US5573751B1 (en) 1991-09-17 1999-03-09 Sonuc Pharmaceuticals Inc Persistent gaseous bubbles as ultrasound contrast media
US5573751A (en) 1991-09-17 1996-11-12 Sonus Pharmaceuticals, Inc. Persistent gaseous bubbles as ultrasound contrast media
US5648062A (en) 1992-01-09 1997-07-15 Nycomed Imaging As Contrast agents consisting of galactose particles
US5567412A (en) 1992-01-09 1996-10-22 Nycomed Imaging As Contrast agents consisting of galactose particles and an amphilic carboxylic acid
US5558856A (en) 1992-01-09 1996-09-24 Nycomed Imaging As Microbubble-generating contrast agents for ultrasound and magnetic resonance imaging
US5928626A (en) 1992-01-09 1999-07-27 Nycomed Imaging As Contrast agents, consisting of carbohydrate particles
US5614169A (en) 1992-01-09 1997-03-25 Nycomed Imaging As Contrast agents, consisting of galactose particles and an amphilic carboxylic acid
US5637289A (en) 1992-01-09 1997-06-10 Nycomed Imaging As Contrast agents, consisting of galactose particles
US5413774A (en) 1992-01-23 1995-05-09 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US6187288B1 (en) 1992-02-11 2001-02-13 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasonic echography
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5545395A (en) 1992-08-13 1996-08-13 Bracco Research, S.A. Method of imaging using encapsulated magnetite particles
US5587199A (en) 1992-08-13 1996-12-24 Bracco International B.V. Process of preparing particles for NMR imaging
US5908610A (en) 1992-11-02 1999-06-01 Bracco International B.V. Stable microbubble suspensions comprising saturated phospholipios for ultrasonic echography
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5597549A (en) 1992-11-02 1997-01-28 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5686060A (en) 1992-11-02 1997-11-11 Bracco International Bv Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography
US5352436A (en) 1992-11-02 1994-10-04 Drexel University Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same
US6183725B1 (en) 1992-12-16 2001-02-06 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5846518A (en) 1992-12-16 1998-12-08 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media contrast agents containing the media and method
US6506938B1 (en) 1993-07-30 2003-01-14 Bracco International B.V. Process for the purifying of iopamidol
US5958373A (en) 1993-09-07 1999-09-28 Nycomed Salutar Inc. Polychelants as contrast enhancing agents
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US6274120B1 (en) 1994-02-15 2001-08-14 Nycomed Imaging As Dry microparticles for use as a contrast agent
US6110444A (en) 1994-03-01 2000-08-29 Nycomed Imaging As Gas-containing microcapsules useful as contrast agents for diagnostic imaging
US5676928A (en) 1994-03-28 1997-10-14 Nycomed Imaging As Liposomes
US5958376A (en) 1994-09-23 1999-09-28 Nycomed Imaging As Iodinated X-ray contrast media
US5958375A (en) 1994-09-23 1999-09-28 Nycomed Imaging As Urea-linked, iodinated bis phenyl compounds for X-ray contrast media
US5882628A (en) 1994-09-23 1999-03-16 Nycomed Imaging As Contrast media
US5993780A (en) 1994-09-23 1999-11-30 Nycomed Imaging As Contrast media
US6310243B1 (en) 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
US5980937A (en) 1994-09-30 1999-11-09 Bracco Research S.A. Liposomes with enhanced entrapment capacity and their use in imaging
US5856570A (en) 1994-11-29 1999-01-05 Bracco International B.V. Process for preparing 5-amino-2,4,6-triiodoisophthalic acid dichloride by chlorination of the corresponding acid in the presence of a tertiary amine salt or quaternary ammonium salt
US5827504A (en) 1994-12-16 1998-10-27 Bracco Research S.A. Method of echographic imaging using frozen gasbubble suspensions
US5830435A (en) 1994-12-16 1998-11-03 Bracco Research S.A. Method of storing frozen microbubble suspensions
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6217850B1 (en) 1995-06-07 2001-04-17 Nycomed Imaging As Method of making lyophilized microbubble compositions useful as contrast agents
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5689002A (en) 1995-09-08 1997-11-18 Bracco International B.V. Process for the crystallization from water of (S)-N,N'-bis 2-hydroxy-1-(hydroxymethyl)ethyl!-5- 2-hydroxy-1-oxopropyl)amino!-2,4,6-triiodo-1,3-benzendicarboxamide
US6123920A (en) 1996-01-10 2000-09-26 Nycomed Imaging As Superparamagnetic contrast media coated with starch and polyalkylene oxides
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
US6221337B1 (en) 1996-02-19 2001-04-24 Nycomed Imaging As Microbubbles surrounded by a monolayer of negatively charged phospholipids as contrast agents
US7892522B2 (en) 1996-08-02 2011-02-22 Ge Healthcare As Contrast agents
US6165378A (en) 1996-08-30 2000-12-26 Meito Sangyo Kabushiki Kaisha Polysaccharide derivative/magnetic metal oxide composite
US6680047B2 (en) 1996-10-28 2004-01-20 Amersham Health As Diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6264917B1 (en) 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US7182934B2 (en) 1996-10-28 2007-02-27 Ge Healthcare As Contrast agents
US6051207A (en) 1996-10-28 2000-04-18 Nycomed Imaging As Contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6054118A (en) 1997-01-22 2000-04-25 Nycomed Imaging As Contrast agents comprising two types of gas-containing microparticles
US6177061B1 (en) 1997-04-23 2001-01-23 Nycomed Imaging As Contrast agents comprising an azeotropic mixture of two gases for ultrasound investigations
US7413727B2 (en) 1997-04-24 2008-08-19 Ge Healthcare As Contrast agents
US6045777A (en) 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6716412B2 (en) 1997-09-15 2004-04-06 Imarx Therapeutics, Inc. Methods of ultrasound treatment using gas or gaseous precursor-filled compositions
US6350908B1 (en) 1998-09-11 2002-02-26 Bracco Imaging S.P.A Process for the preparation of S-N,N′-bis [2-hydroxy-1-(hydroxymethyl) ethyl]-5- [(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
US7374745B2 (en) 1998-10-12 2008-05-20 Mallinckrodt, Inc. Ultrasound contrast agents
US6420603B1 (en) 1998-11-27 2002-07-16 Bracco International B.V. Process for the preparation of n,n'-bis[2,3-dihydroxypropyl]-5-[(hydroxyacetyl) methylamino]-2, 4,6-triiodo-1, 3-benzenedi carboxamide
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US7115778B2 (en) 1999-02-26 2006-10-03 Bracco Imaging, S.P.A. Process for the preparation of iopamidol
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6406680B1 (en) 1999-09-17 2002-06-18 Nycomed Imaging As X-ray contrast agents
US7745590B1 (en) 2001-11-13 2010-06-29 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
US20040019282A1 (en) 2002-07-29 2004-01-29 Mullen Linda J. Hybrid lidar-radar for medical diagnostics
US7368099B2 (en) 2003-02-27 2008-05-06 Kyushu University, National University Corporation MRI contrast agents
US20040249257A1 (en) 2003-06-04 2004-12-09 Tupin Joe Paul Article of manufacture for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US20100234720A1 (en) 2003-06-04 2010-09-16 Tupin Jr Joe Paul System and method for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US7785568B2 (en) 2004-04-21 2010-08-31 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7588751B2 (en) 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
US7592482B2 (en) 2005-09-13 2009-09-22 Bracco Imaging S.P.A. Process for the preparation of contrast agents
US7767196B2 (en) 2005-11-21 2010-08-03 The University Of Hong Kong Optimized relaxivity and specificity hepatobiliary MRI contrast agent
US7485753B2 (en) 2005-12-02 2009-02-03 Ge Healthcare As Contrast agents
US7892520B2 (en) 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
US20100322868A1 (en) 2007-07-12 2010-12-23 Mikkel Thaning Contrast agents
US20090192384A1 (en) 2008-01-30 2009-07-30 Siemens Aktiengesellschaft Medical unit and method for improving examination and treatment workflows
WO2010124117A2 (en) 2009-04-22 2010-10-28 Lifewave, Inc. Fetal monitoring device and methods
US20100292559A1 (en) 2009-05-14 2010-11-18 Thilo Hannemann Radar-equipped patient bed for a medical imaging apparatus, and operating method therefor
US7754920B1 (en) 2009-07-21 2010-07-13 Ge Healthcare As Solvent reduction in crystallisation of intermediate for non-ionic X-ray contrast agents

Also Published As

Publication number Publication date
WO2012136813A9 (en) 2013-03-14
WO2012136813A3 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
Sundin et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations
Oudkerk et al. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging.
Zhang et al. Hyaluronic acid-modified magnetic iron oxide nanoparticles for MR imaging of surgically induced endometriosis model in rats
Biscaldi et al. Bowel endometriosis: CT-enteroclysis
CN107847445B (en) Encapsulated gas or partial vacuum CT contrast material
JP6843787B2 (en) Intestinal CT contrast material with low Z atoms
US9820672B2 (en) Colon screening by using magnetic particle imaging
Zheng et al. Liposome contrast agent for CT‐based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG‐PET and histology
Runge et al. Future directions in magnetic resonance contrast media
Zhang et al. Comparison of three-dimensional negative-contrast CT cholangiopancreatography with three-dimensional MR cholangiopancreatography for the diagnosis of obstructive biliary diseases
Cui et al. Feasibility and usefulness of using swallow contrast-enhanced ultrasound to diagnose Zenker's diverticulum: preliminary results
Rieber et al. MRI of the abdomen with positive oral contrast agents for the diagnosis of inflammatory small bowel disease
WO2012136813A2 (en) Agents for medical radar diagnosis
WO2011064577A1 (en) Contrast agents for medical microwave imaging
Lauenstein et al. Magnetic resonance colonography for colorectal cancer screening
US7582283B2 (en) Contrast agents to improve gastrointestinal tract opacification during abdominal and pelvic CT scans
Lee et al. Comparison of static-fluid or excretory magnetic resonance urography with computed tomography urography for visualization of nondilated renal pelvises and ureters in healthy Beagles
Sinha Intestinal imaging: the last frontier
KR102158794B1 (en) Multipurpose Contrast Agent for Radiography and Ultrasonography
Buthiau et al. Virtual endoscopy
Lu et al. SPIO-loaded Nanostructured Lipid Carriers for T2-Weighted Magnetic Resonance Imaging of Hepatocarcinoma
Niemi et al. Superparamagnetic particles as gastrointestinal contrast agent in magnetic resonance imaging of lower abdomen
Saar et al. Magnetic resonance colonography: a promising new technique
US11207429B2 (en) Method and compositions for orally administered contrast agents for MR imaging
Kim Development of Nanoparticle-Based Contrast Agents for Applications with Conventional and Photon-Counting CT Imaging

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2